NEWARK, Calif., Jan. 30, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Martin McGlynn will present at the following conferences:
- 16th Annual BIO CEO & Investor Conference in New York on February 10, 2014, at 2:30 p.m. EST
- Leerink Swann 2014 Global Healthcare Conference in New York on February 12, 2014 at 3:00 p.m. EST
As Martin McGlynn, CEO StemCells, Inc., indicated in his January 6 letter to shareholders, one of his priorities is to ensure that StemCells, Inc. is effectively communicating the Company's outlook and progress. Accordingly, he will be presenting at these two conferences in February and additionally plans to present at the Alliance for Regenerative Medicine's Investor Conference on March 26, 2014.
A live webcast of the presentations will be available through the Company's corporate website http://www.stemcellsinc.com. Interested parties are encouraged to connect to the website at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary. In addition, you may directly access the webcast through the following links:
- 16th Annual BIO CEO & Investor Conference: http://www.veracast.com/webcasts/bio/ceoinvestor2014/11137126671.cfm
- Leerink Swann 2014 Global Healthcare Conference: http://leerink.metameetings.com/confbook/healthcare14/directlink?ticker=STEM
A replay will also be accessible for 90 days through the Company's website.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. In a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children, the Company has shown preliminary evidence of progressive and durable donor-derived myelination in all four patients transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland, Canada and the United States, and has reported positive interim data for the first three patients. The Company is also conducting a Phase I/II clinical trial in dry age-related macular degeneration (AMD) in the United States. In addition, the Company is pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine (CIRM). StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand. Further information about StemCells is available at http://www.stemcellsinc.com.
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, and is subject to the safe harbors created therein. These statements include, but are not limited to, the prospect for screening and then enrolling additional patients with incomplete spinal cord injury; the prospect for evaluating trial patients for changes in their sensation, motor function and bowel/bladder function; the potential of the Company's HuCNS-SC cells to treat spinal cord injury and other central nervous system diseases and disorders; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including the fact that additional trials will be required to demonstrate the safety and efficacy of the Company's HuCNS-SC cells for the treatment of any disease or disorder; uncertainty as to whether applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury or in future clinical trials of proposed therapies for other diseases or conditions; uncertainties regarding the Company's ability to obtain the increased capital resources needed to continue its current and planned research and development operations; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company's cell-based programs will prove safe and clinically effective and not cause tumors or other adverse side effects; and other factors that are described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and in its subsequent reports on Form 10-Q and Form 8-K.